U.S. Markets open in 5 hrs 53 mins

Aridis Pharmaceuticals, Inc. (ARDS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
7.24-0.53 (-6.82%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.77
Open8.00
Bid0.00 x 1200
Ask0.00 x 800
Day's Range7.00 - 8.00
52 Week Range3.80 - 10.18
Volume20,185
Avg. Volume11,363
Market Cap64.605M
Beta (5Y Monthly)0.06
PE Ratio (TTM)N/A
EPS (TTM)-2.70
Earnings DateAug 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.60
  • Aridis Pharmaceuticals Reports Positive Preclinical Efficacy Data of a Highly Effective Inhaled Treatment Supporting a Proposed Self-Administered Therapy for COVID-19 Patients
    PR Newswire

    Aridis Pharmaceuticals Reports Positive Preclinical Efficacy Data of a Highly Effective Inhaled Treatment Supporting a Proposed Self-Administered Therapy for COVID-19 Patients

    Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the development of a highly neutralizing monoclonal antibody AR-711, discovered from convalescent COVID-19 patients, that successfully eliminated all detectable SARS-CoV-2 virus in infected animals at substantially lower doses than parenterally administered (injected) COVID-19 monoclonal antibodies ("mAb"). The potency of AR-711 and its direct delivery to the lungs by inhaled administration may facilitate broader treatment coverage and dose sparing not achievable by parenteral administration.

  • Aridis Pharmaceuticals Announces $8.5 Million Registered Direct Offering
    PR Newswire

    Aridis Pharmaceuticals Announces $8.5 Million Registered Direct Offering

    Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (the "Company"), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced that it has entered into a securities purchase agreement with certain institutional investors with extensive backgrounds in life sciences and biotechnology investing to purchase in a registered direct offering 1,134,470 shares of common stock for $7.4925 per share.

  • Aridis Announces Agreement with the FDA on Updated Phase 2 Clinical Trial Design for AR-501
    PR Newswire

    Aridis Announces Agreement with the FDA on Updated Phase 2 Clinical Trial Design for AR-501

    Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced it has reached an agreement with the US Food and Drug Administration (FDA) to simplify the Company's AR-501 Phase 2 trial design for the treatment of chronic lung infections associated with cystic fibrosis (CF).